Clarity Wealth Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)

Clarity Wealth Advisors LLC increased its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 4.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,938 shares of the company’s stock after acquiring an additional 969 shares during the quarter. Johnson & Johnson makes up about 1.3% of Clarity Wealth Advisors LLC’s investment portfolio, making the stock its 25th largest position. Clarity Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,787,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. AMI Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 3.8% during the first quarter. AMI Investment Management Inc. now owns 22,018 shares of the company’s stock valued at $3,483,000 after purchasing an additional 810 shares in the last quarter. Chatham Capital Group Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the 1st quarter. Chatham Capital Group Inc. now owns 51,194 shares of the company’s stock valued at $8,098,000 after acquiring an additional 309 shares during the period. Waterway Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $822,000. Strata Wealth Advisors LLC grew its stake in Johnson & Johnson by 219.2% in the first quarter. Strata Wealth Advisors LLC now owns 5,927 shares of the company’s stock valued at $938,000 after purchasing an additional 4,070 shares during the last quarter. Finally, Sandy Cove Advisors LLC raised its holdings in Johnson & Johnson by 4.4% in the first quarter. Sandy Cove Advisors LLC now owns 5,597 shares of the company’s stock worth $885,000 after purchasing an additional 238 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.2 %

JNJ stock opened at $146.42 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The firm’s fifty day simple moving average is $148.14 and its 200-day simple moving average is $154.05. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a market capitalization of $352.39 billion, a P/E ratio of 9.13, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm earned $2.68 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.39%. The ex-dividend date was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Bank of America lowered their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $174.07.

Read Our Latest Analysis on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.